Deutsche bank took its CME Group [CME] rating to the equivalent of Hold from Buy, and the price target to $196.0, in a research note dated 2021-01-08. That figure represents around a -1.41% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with JP Morgan’s analysts upgrading the shares from “an Underweight” rating to “a Neutral” rating in a research note to investors issued in early January. Meanwhile, Atlantic Equities had raised its rating on CME to “an Overweight” from the earlier “Neutral”, in a research note produced for clients September 23, 2020. In addition, Loop Capital launched coverage on September 11, 2020. The research firm rated CME “a Sell”.
Is CME Group Inc. [NASDAQ:CME] a Good Buy Right Now?
It should be noted that CME technical indicators for short, intermediate as well as long term progress have placed an overall average of 72% as Buy. The average signal changed from 40% Buy in the last week and compares with 24% Buy in the past month. Data from CME Group Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 1.69 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 1.81 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 1.65 million shares.
CME Price Performance
On Wall Street, CME Group Inc. [NASDAQ:CME] finished Thursday’s session up 2.81% at $198.81. The stock went up to $199.30 at the same session while its lowest single day price was $195.01. In the last five days, it saw a rise of about 11.69%, CME Group Inc. shares gained by almost 9.21% since the beginning of the year. However, the share price has dropped to as low as -10.54% below its one year high. On 01/07/21, the company shares recorded $199.30, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/05/21, the same year at $177.51. The company’s shares have declined by -2.18% in the past year. The 50-day SMA achieved is $172.66 while the 200-day SMA is $172.78. Volume dropped to 2.79 million from 4.45 million in the previous session.
CME Group Inc. [CME] Valuation Measures
Notably, CME Group Inc. [CME] stock cannot be classified as a good candidate in the listing of underestimated low-priced Financial Data & Stock Exchanges companies to purchase soonest possible with the prevailing 12-month PE ratio of 33.13. The measure means the stock is exchanging at a premium as compared to the 17.71x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 14.17 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 3.78 which means CME serve an unattractive investment opportunity compared to its competitors.
CME Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 196.11 level, and in case of violation of this particular level, it will cause more drop to 193.42 level. On the upper level, 202.00 is still the key resistance. The stock may increase to the subsequent resistance at 200.40. The Relative Strength Index (RSI) pinned on the 14-day chart is 76.32, implying a overbought technical stance while the MACD stands at 7.55, meaning price will increase in the next trading period. Percent R indicator moved to 2.21%, implying bullish price movement. Stochastic %K at 69.90% suggest selling the stock.
What is the short interest in CME Group Inc.?
Short interest in the CME Group Inc. stock has plunged, decreasing by -0.12 million shares to total 5.78 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 5.66 million, data from Yahoo Finance shows. The increase of 2.08% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 1.81% of the overall float for the stock.
CME Group Inc.’s Biggest Shareholders: Who Owns CME Group Inc. [CME]?
Filings by Capital Research & Management Co showed that the firm now holds a total of 34,733,807 shares or roughly 9.68% of the outstanding CME shares. This means their shares have reduced by -14,008 from the 34,733,807 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $4,724,642,900. Details in the latest 13F filings reveal that BlackRock Fund Advisors disposed off their -2.63% stake valued at $2,930,439,600 while SSgA Funds Management, Inc. cut theirs at $2,794,122,035. During the last quarter, BlackRock Fund Advisors liquidated -452,820 of its shares in CME Group Inc. while SSgA Funds Management, Inc. sold -90,465 shares. The Capital Research & Management Co’s holdings currently number 11,139,344 shares at $2214612980.64. According to the firm’s last 13F report, Capital Research & Management Co shares in the company at filing stood at 10,932,713 shares, roughly $1,913,552,756.
CME Earnings Forecast For The Current Quarter
CME Group Inc. [CME] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $1.1B and an earnings per share of $1.39 for Dec 2020. Looking further ahead, the company is expected to report revenue of $1.19B at an EPS of $1.63 for Mar 2021. The estimates represent downside of -1.70% and -0.81% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
CME Earnings Estimates For The Current Year
For the financial year, CME Group Inc. [NASDAQ:CME] is expected to bring in revenue of $4.91B. The returns are nearly $40.0 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 6.78, lower than that of FY19 by -$0.02. Estimates put this year’s earnings growth at -0.30%, -0.90% for the next, and at an annual 3.18% over the next 5-year period. As for sales, forecasts are for an increase of 0.90% in the current fiscal year and a further -1.70% over the following year.